Analyst firms · Wolfe Research · RMD

Wolfe Research RMD price target and rating history

ResMed Inc. (RMD) · Health Care

Wolfe Research rates ResMed Inc. (RMD) Underperform with a $180 price target, as of its latest action on Sep 18, 2024. It has published 3 rating actions on RMD since April 2022, including 0 upgrades and 2 downgrades. Across 5 firms with a RMD price target in the last 12 months, the median target is $235.

Current rating

Underperform

Price target

$180

Median target, all firms

$235

Actions on RMD

3

Wolfe Research price target on RMD

Every Wolfe Research rating on RMD

• Sep 18, 2024
  DowngradeWolfe Research downgrades to Underperform from Peer Perform, price target $180
• Sep 29, 2023
  DowngradeWolfe Research downgrades to Peer Perform from Outperform
• Apr 6, 2022
  InitiateWolfe Research starts coverage at Outperform, price target $280

How other firms rate RMD

Each firm's latest rating and stated target in the last 12 months.

Questions about Wolfe Research and RMD

What is Wolfe Research's price target for RMD?

Wolfe Research's latest stated price target for ResMed Inc. (RMD) is $180, from its action on Sep 18, 2024.

What is Wolfe Research's rating on RMD?

Wolfe Research rates RMD Underperform, a bearish rating, as of Sep 18, 2024.

When did Wolfe Research last change its view on RMD?

On Sep 18, 2024, Wolfe Research downgrades to Underperform from Peer Perform, price target $180.

How does Wolfe Research's RMD target compare with other analysts?

Across 5 firms with a RMD price target in the last 12 months, the median target is $235.

More RMD rating histories

• RBC Capital Markets13
• Citigroup8
• Morgan Stanley4
• Robert W. Baird4
• CLSA5
• Needham3
• J.P. Morgan6
• BofA Securities3

All Wolfe Research ratingsRMD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.